KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Treatment Naïve Patients With PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Latest Information Update: 06 Feb 2024
At a glance
- Drugs MK-4830 (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-01B; MK-3475-01B-KEYNOTE-01B
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 20 Dec 2023 Planned End Date changed from 13 Feb 2032 to 17 Sep 2025.
- 20 Dec 2023 Planned primary completion date changed from 13 Feb 2032 to 17 Sep 2025.
- 08 Nov 2023 Status changed from recruiting to active, no longer recruiting.